StockStory flags Chemed, Bristol-Myers Squibb, and Viatris as healthcare stocks to avoid

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory identifies three healthcare stocks that investors should keep off their radar due to weak financial performance. Chemed, with a market cap of $6.65 billion, saw annual revenue growth of just 4% over five years and EPS growth of only 2.8% annually, while its diminishing returns on capital suggest drying profit pools. Bristol-Myers Squibb, valued at $125.6 billion, posted 2.6% annual revenue growth over five years, a 10.4 percentage point drop in adjusted operating margin, and a 1.7% annual EPS decline despite revenue gains. Viatris, with a $20.12 billion market cap, experienced a 2.6% annual sales decline over two years, a 9.2% annual EPS drop over five years, and negative returns on capital indicating value destruction.

Impact on stocks 3

Biotech & Genomic Medicine▼ · 2 stocks
Bristol-Myers Squibb Company
BMY
▼ NegativeCapitalrelevance

Article highlights weak financial performance: 2.6% annual revenue growth, 10.4pp drop in adjusted operating margin, and 1.7% annual EPS decline.

Viatris Inc
VTRS
▼ NegativeCapitalrelevance

Article highlights weak financial performance: 2.6% annual sales decline, 9.2% annual EPS drop, and negative returns on capital.

Aging Population▼ · 1 stocks
Chemed Corp
CHE
▼ NegativeCapitalrelevance

Article highlights weak financial performance: 4% annual revenue growth, 2.8% annual EPS growth, and diminishing returns on capital.

© 2026 MarketDXNews